Skip to main content
SupplementScience

Vitamin K2 MK-4 vs MK-7

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

MK-7 is better for most people due to its 72-hour half-life, lower dosing requirements, and stronger evidence for bone...

MK-7 is better for most people due to its 72-hour half-life, lower dosing requirements, and stronger evidence for bone and cardiovascular health. MK-4 is preferred for brain health and is used as an osteoporosis drug in Japan at 45mg doses.

Head-to-Head Comparison

CriteriaVitamin K2 MK-4MK-7Winner
BioavailabilityModerate — rapid absorption but short half-life (1-2h)High — long half-life (~72h), accumulates with daily dosingMK-7
Clinical EvidenceStrong for bone (Japan) — limited Western RCTsStrong — multiple RCTs for bone density and arterial stiffnessMK-7
GI TolerabilityGood — well tolerated at standard dosesExcellent — very low doses, minimal GI burdenMK-7
Cost$0.10-0.25/serving (standard dose)$0.15-0.40/servingVitamin K2 MK-4
Half-Life & Dosing Convenience1-2 hours — requires multiple daily doses~72 hours — once daily is sufficientMK-7

Detailed Analysis

Bioavailability

MK-7's extended half-life of approximately 72 hours allows it to reach steady-state blood levels with once-daily dosing, while MK-4's 1-2 hour half-life requires multiple daily doses to maintain therapeutic levels.

Clinical Evidence

MK-7 has more published Western RCTs demonstrating benefits for osteocalcin carboxylation and arterial calcification. MK-4 has robust Japanese clinical data supporting its use as an approved osteoporosis treatment at 45mg/day.

GI Tolerability

Both forms are well tolerated, but MK-7's effective doses (100-200mcg) are far smaller than MK-4's therapeutic doses (15-45mg), resulting in less GI burden overall.

Cost

MK-4 supplements at standard supplemental doses (1-5mg) tend to be cheaper. However, at the therapeutic 45mg dose used in Japanese studies, MK-4 becomes significantly more expensive than MK-7.

Half-Life & Dosing Convenience

MK-7's dramatically longer half-life means a single daily dose maintains stable blood levels. MK-4's rapid clearance means it must be taken 2-3 times daily for sustained carboxylation of vitamin K-dependent proteins.

Our Verdict

MK-7 wins for most people: once-daily dosing, longer half-life, and strong cardiovascular and bone evidence. Choose MK-4 for targeted brain support or Japanese-protocol osteoporosis treatment.

Which Vitamin K2 (MK-7) Form Is Right for You?

Answer below to get a personalized recommendation.

What matters most to you?
Learn more about
Vitamin K2 (MK-7)

Frequently Asked Questions

Can I take MK-4 and MK-7 together?

Yes, combining MK-4 and MK-7 is safe and may offer complementary benefits. MK-7 provides sustained background K2 activity for bones and arteries, while MK-4 may offer additional brain tissue benefits due to its ability to cross into neural tissue. Some premium supplements include both forms.

Which is better for bone health?

Both are effective, but MK-7 has more accessible clinical evidence at low doses (100-200mcg). MK-4 is approved as an osteoporosis drug in Japan at 45mg/day (far higher than typical supplements). For general bone support, MK-7 at 100-200mcg daily is the more practical choice.

Is MK-7 worth the extra cost over MK-4?

For most people, yes. MK-7's 72-hour half-life means once-daily dosing at 100-200mcg maintains stable blood levels, while MK-4 clears in 1-2 hours and requires multiple doses. The convenience and consistent K2 activity make MK-7 worth the modest price premium for daily supplementation.

Does MK-4 actually reach the brain better than MK-7?

Research suggests MK-4 is the predominant form of vitamin K2 found in brain tissue, regardless of dietary source. The body appears to convert other K vitamins into MK-4 in the brain. Supplemental MK-4 may support this pool more directly, though more human studies are needed to confirm cognitive benefits.

References

  1. Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E (2013). Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International. DOI PubMed
  2. Sato T, Schurgers LJ, Uenishi K (2012). Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutrition Journal. DOI PubMed